Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 2/20 | 0.70 |
| ▸ | RAB9A | P51151 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LTA4H | P09960 | 2/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA1 | P00915 | 1/20 | 0.62 |
| ▸ | CA2 | P00918 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.62 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | GBA1 | P04062 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295527 | 0.86 | MEN1 (0.77) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL27710659 | 0.85 | RAB9A (0.71) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL321314 | 0.84 | NOX1 (0.62) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4666213 | 0.84 | RAB9A (0.66) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL12585091 | 0.84 | NOX1 (0.73) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL31662300 | 0.83 | EPHX1 (0.60) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL321103 | 0.83 | LTA4H (0.68) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL6688599 | 0.83 | NOX1 (0.61) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL23747763 | 0.83 | NPC1 (0.78) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2170643 | 0.82 | LTA4H (0.76) | NOX1RAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | NOX1 567/4885RAB9A 1800/4885SMN1; SMN2 3162/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | NOX1 392/4885RAB9A 1702/4885SMN1; SMN2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.